Original Research

The First Malaysian Multidisciplinary Team Heart Failure Clinic: A Tertiary Cardiac Centre Experience

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating


Aims: There remains a large emphasis on optimisation of guideline-directed medical therapy (GDMT) during the ‘vulnerable phase’ of acute heart failure (HF). Multidisciplinary team heart failure (MDT-HF) clinics have been shown to be beneficial in increasing key GDMT prescriptions. The aim of this study was to report on the authors’ experience running the first Malaysian early, post-discharge MDT-HF clinic. Methods: A retrospective review of the MDT-HF clinic was conducted in Institut Jantung Negara, Malaysia, over a 3-year period (2019–22). Results: A total of 186 patients and 488 clinic encounters were identified. Patients were mainly of New York Heart Association functional class II (45.2%) and had a mean left ventricular ejection fraction of 26.1%. Blood investigations on average were stable, aside from estimated glomerular filtration rate (≤60 ml/min/1.73 m2 in 53.2% of patients) and NT-pro-brain natriuretic peptide (mean of 5,201 pg/ml). Common comorbidities included diabetes (60.0%), hypertension (60.0%), dyslipidaemia (46.2%) and chronic kidney disease (38.2%). A high proportion of new prescriptions and uptitration of medication were for key GDMTs, while the majority of downtitrations were for diuretics. A substantial number of patients were on three or four GDMTs (37.6% and 49.5%, respectively). Counselling provided during the MDT-HF clinic was also analysed, which included education on selfcare and medication management, and lifestyle counselling. Conclusion: MDT-based services offer evidence-based, holistic care to HF patients. Hopefully, this description of the establishment of the first MDT-HF clinic should encourage the development of similar services across the region.

Disclosure:The authors have no conflicts of interest to declare.



Published online:

Informed Consent:

All individuals included in the study have given written informed consent. Patients also provided written informed consent regarding the publishing of their data.

Data Availability Statement:

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Ethics Approval Statement:

The Institut Jantung Negara Research Ethics Committee (IJNREC) reviewed and approved this study. The committee is constituted and operates according to the Malaysian Guidelines for Good Clinical Practice (GCP) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)– GCP guidelines. This study conforms to the principles of the Declaration of Helsinki, GCP and the laws and regulations of Malaysia, in which the research was conducted.

Acknowledgements:The authors acknowledge the Cardiology Department of Institut Jantung Negara for their support in the submission of the manuscript, and the Clinical Research Department and Management Information Systems Department for allowing access to data. The authors also acknowledge the biostatistics and data repository sector of the National Institute of Health, Setia Alam for the data linkage service provided, and the National Registration Department (JPN) for their willingness to share their mortality records for research purposes.

Author contributions:

Conceptualisation: RERS, HBK, ISS, WJQ, SHO; data curation: MAS, ISS, JJ, STD, CJAW; formal analysis: RERS, HBK, ISS, AMG; investigation: RERS, HBK, ISS, WJQ, SHO, AMG; methodology: RERS, HBK, ISS, WJQ, SHO, AMG; project administration: MAS, ISS, AAAR, CKT, AMG; resources: MAS, ISS, AAAR, CKT, AMG; software: MAS, ISS; supervision: AAAR, CKT, AMG; validation: RERS, HBK, MAS, WJQ, SHO, ISS, AAAR, CKT, AMG; visualisation: RERS, ISS; writing – original draft: RERS, HBK, ISS, WJQ, SHO, JJ, STD, CJAW; writing – review & editing: AAAR, CKT, AMG.

Correspondence Details:Raja Ezman Raja Shariff, Universiti Teknologi MARA Kampus, Jalan Hospital, 47000 Sungai Buloh, Malaysia. E: rajaezman@gmail.com

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Approximately 25% of patients hospitalised for acute decompensated heart failure (ADHF) are at risk of future re-hospitalisation or mortality within 1 month of discharge.1 Rates of mortality and hospitalisation are equally poor in Malaysia, with 30-day mortality and rehospitalisation reaching levels as high as 13.1–15.7% and 4.1–11.2%, respectively, based on local data.2,3 Over the past decade, there has remained a large emphasis on the optimisation of guideline-directed medical therapy (GDMT) during the ‘vulnerable phase’ following decompensation, with a focus on in-hospital initiation of GDMT to overcome prescription inertia among clinicians.4,5 Unfortunately, pressures on hospital systems restrict the duration of inpatient stay, which often lasts between 5 and 9 days and is often insufficient to concurrently manage acute congestion while attempting to uptitrate GDMT doses.2,3,6

The Multidisciplinary Team Heart Failure Clinic in Institut Jantung Negara

Article image

Of the various strategies proposed over the past decade, multidisciplinary team heart failure (MDT-HF) clinics have been shown to be beneficial in increasing key GDMT prescriptions, with strong recommendations made by both the European Society of Cardiology (class 1a) and American College of Cardiology (class 1b), especially in vulnerable patients.7,8 The aim of this study was to report on our experience running an early, post-discharge MDT-HF clinic – the first of its kind in Malaysia.


Study Centre

A retrospective review was conducted at our institution – Institut Jantung Negara (IJN), Malaysia. IJN is a major cardiac tertiary centre in Kuala Lumpur, and is also the major referral centre for advanced heart failure (HF) care, including heart transplantation, and left ventricular assist device and complex cardiovascular implantable electronic device (CIED) implantation. There is also an active inpatient and outpatient HF service providing multidisciplinary care involving cardiologists, cardiothoracic surgeons, pharmacists, nurse specialists, physiotherapists and cardiac rehabilitation specialists.

At the institution, all acute admissions for HF are entered into a local database as part of an ADHF registry (Figure 1). Patients admitted for ADHF are also given a discharge checklist to ensure that necessary medications and counselling are provided prior to discharge. Patients are also concurrently screened by our team of nurse specialists and ward nurses for eligibility for follow-up under our teleconsultation or MDT-HF clinic services. The MDT-HF clinic was first initiated in July 2019 and continues to be an ongoing service provided to all clinicians at IJN via formal inpatient referral to the HF team (Figure 1). The HF team consists of two consultant HF cardiologists and one or two specialist registrars. The clinic reviews up to 10 patients per session, together with a team consisting of doctors, HF pharmacists, HF nurses, a physiotherapist, dietitian and counsellor. Patients seen in the MDT-HF clinic include those recently admitted for ADHF and are often seen in the 7–12 days after discharge.

The main objectives in the MDT-HF clinic primarily revolve around improving GDMT optimisation and functional status (i.e. physical and mental wellbeing), symptom monitoring, and monitoring for adverse effects related to pharmacotherapy. During the initial stages of designing the MDT-HF clinic, patients were required to have an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2 and have good social support to be eligible for referral, to ensure that they would benefit from the clinic and to limit barriers to successful uptitration of GDMT. However, over time, this requirement was enforced less and less, and the clinic has since included consultations with patients who have end-stage renal failure and those on renal replacement therapy. Given that medication prescription at our institution is fully funded by the institution, good social support was essential in our setting to ensure adherence to GDMT because it is often costly. However, the eGFR level used remains arbitrary with no objective measure per se, and, given that all patients initially seen in our clinic were never excluded, we have since omitted this from our requirement as of June 2022.

Following optimisation of GDMT, patients are subsequently discharged from the MDT-HF clinic (after an average duration of 6–12 weeks of follow-up) to one of the following: a general cardiology clinic for routine care; an advanced HF clinic for consideration of advanced HF therapy (i.e. ventricular assist device implantation or heart transplantation); or an electrophysiology clinic for consideration of CIED, if eligible for either.

Study Design and Study Population

Data from ambulatory patients reviewed in the MDT-HF clinic between 1 July 2019 and 31 June 2022 were obtained through the IJN MDT-HF registry. Selection was through universal sampling. A total of 186 patients and 488 clinic encounters were identified.

Information gathered included baseline demographics, New York Heart Association (NYHA) functional class, left ventricular ejection fraction (LVEF), comorbidities, clinical variables (systolic and diastolic blood pressure [SBP and DBP], heart rate [HR], symptoms and signs), blood investigations and clinical outcomes. Data on groups of medication prescribed, the pattern of prescription (initiation, increment and decrement of medication doses) and number of GDMTs prescribed were also analysed. Furthermore, information on counselling provided to the patients by both pharmacists and HF nurses was also obtained. Descriptive statistics were used to summarise baseline demographic, comorbidities, vital signs, blood investigation and clinical outcomes. Categorical variables are expressed as frequencies and percentages. Continuous variables are summarised as the mean and SD, or median and IQR.

The IJN Research Ethics Committee (IJNREC) reviewed and approved this study. The committee is constituted and operates according to the Malaysian Guidelines for Good Clinical Practice (GCP) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)–GCP guidelines. The study conforms to the principles of the Declaration of Helsinki, GCP and the laws and regulations of Malaysia, in which the research is conducted.


In total, 186 patients were reviewed in the MDT-HF clinic between 1 July 2019 and 30 June 2022, with a total of 488 clinic encounters (Table 1). Of these, 148 patients (79.6%) were male (Table 2). The mean and median age of patients attending the clinic were 61 ± 14 years and 64 years, respectively, the majority (51.6%) of whom were in the 60–80-year age range. Patients were mainly of NYHA functional class II (45.2%), which usually warrants uptitration of medication as per guidelines, thus the need for referral to such services. The mean weight and BMI were 70.1 ± 18.2 kg and 26.3 ± 6 kg/m2. Blood pressure and HR were stable at the time of first clinic review (SBP, DBP and HR 119 ± 19 mmHg, 73 ± 11 mmHg and 73 ± 14 BPM, respectively; Table 2). The mean LVEF was 26.1 ± 8.5%, with the majority of patients having LVEF <30% (61.8%). Although we did not restrict patients with unknown LVEF from being reviewed in the MDT-HF clinic, of the 24 patients with no known LVEF during their initial clinic consultation, all had undergone some form of bedside echocardiography that established the presence of dilated cardiomyopathy with an estimated ejection fraction below 40%.

Blood investigations during each visit, on average, were relatively stable aside from creatinine (137 ± 68 mmol/l), eGFR (53.2% of patients with levels ≤60 ml/min/1.73 m2) and NT-pro-brain natriuretic peptide (NT-proBNP; mean and median of 5,201 ± 7,057 pg/ml and 2,554 pg/ml, respectively; Table 2). Common comorbidities included diabetes (60.0%), hypertension (60.0%), dyslipidaemia (46.2%) and chronic kidney disease (38.2%). The commonest symptoms reported in the clinic were dyspnoea on exertion (28.7%) and reduced effort tolerance (9.4%), and the commonest sign was pitting oedema (23.4%).

Total Number of New Patients and Clinic Visits

Article image

Of the medications prescribed at last clinic review (Table 3), with regard to HF, a substantial proportion of patients were prescribed angiotensin receptor and neprilysin inhibitors (ARNI) (85.5%), β-blockers (83.9%), mineralocorticoid receptor antagonist (MRA) (86.0%) and diuretics (88.2%). There was also a high degree of statin (88.2%) and aspirin (61.8%) prescription. When analysing prescription patterns during each clinic visit, a high proportion of new prescriptions and further uptitration were for ARNI (9.8% and 40.0%, respectively), β-blockers (7.6% and 18.6%, respectively), and MRA (8.2% and 11.9%, respectively). The majority of downtitrations were for diuretics (20.7%), followed by ARNI (5.7%). Of the 28 encounters that had required downtitration of ARNI, 20 of these cases were due to symptomatic hypotension, while the remaining eight were due to worsening renal function beyond the recommended allowance for creatinine rise (with or without hyperkalaemia). A large proportion of patients were on either three or four GDMTs by their last clinic review (37.6% and 49.5%, respectively; Table 3).

Although a large proportion of counselling provided during the MDT-HF clinics centres around appropriate medication use, management of polypharmacy and other medication-related issues (i.e. adherence, self-cessation), a reasonable amount of time is spent on other non-pharmacotherapy-related areas, such as diet and fluid restriction (92.0%), levels of activity permitted (87.3%), weight monitoring (8.36%) and steps to undertake in the event of worsening symptoms (89.5%; Table 4). Common problem areas related to medication identified included difficulty in optimisation of GDMT (41.6%) and non-adherence or self-omission (16.6%) of medication prescription. Of the 186 patients, 28.5% had readmission at some point during the study period, which occurred in the 4.2 ± 5.2 months after their index MDT-HF clinic visit on average (Table 5). None of the patients, however, had any readmission events in the 30 days after their index admission. Furthermore, 10.8% of patients died in the 7.0 ± 7.0 months after their initial visit (Table 5). Of the 20 deaths that occurred, 16 of those were due to worsening ADHF events and four were due to ventricular arrhythmia.


Many factors have been linked to poor uptitration of GDMT in HF patients. These can be largely divided into three main problem areas: healthcare systems factors (e.g. restrictive policies and pricing in using pharmacological therapies, inadequate information technology advances or poor access to speciality and/or multidisciplinary care); clinician factors (e.g. prescribing inertia or gaps in knowledge regarding efficacy, safety or tolerability of new agents); and patient factors (e.g. financial constraints, poor health literacy, fear surrounding changes in management or healthcare services in general).9 Early, post-discharge MDT clinics aim to bridge the gap between multispecialty accessible care and optimum HF care, which is particular pertinent to avoid decompensation of clinical state that often occurs during the vulnerable phase of the disease trajectory.4

Baseline Characteristics

Article image

Baseline Characteristics

Article image

The younger, male-predominant population seen in our MDT-HF clinic is unsurprising and reflects previously reported data on ADHF in Malaysia.2,3,6 The majority of patients had HF with reduced ejection fraction (HFrEF), which again is unsurprising given that it is this group that would most benefit from initiation and uptitration of GDMT.10–12 Furthermore, the majority of ADHF patients in Malaysia consist of patients with HFrEF, which is often ischaemic in aetiology.2,3,6,13,14 The high rates of cardiometabolic risk factors (i.e. hypertension, diabetes, dyslipidaemia and chronic kidney disease) in our patients also mimic that of these registries and studies, and further support this observation.2,3,6

Medication Prescription and Prescribing Pattern During Multidisciplinary Team Clinic Visits

Article image

The deranged renal function in our cohort is a testament to the issue often faced by clinicians in the inpatient setting: acute renal impairment that causes prescription inertia of key pharmacotherapy, despite it being proven repeatedly that rising creatinine following GDMT is not detrimental (and in fact is expected in the majority of cases as an indicator of optimisation).15–18 This further highlights the importance of early follow-up and close monitoring in this group of patients to avoid missing opportunities for treatment uptitration. This is further supported by the raised NT-proBNP levels on clinic presentation, which illustrates the high degree of vulnerability in this cohort.4,11,19

Prescribing patterns observed in our MDT-HF clinics parallel the goals of running such a clinic: a strong focus on initiation and further uptitration of the ‘four pillars of heart failure’.10–12 The majority of patients were on either ARNI, β-blockers or MRA. Fewer patients were on sodium-glucose cotransporter-2 inhibitors (SGLT2Is), possibly because the evidence for SGLT2I use in HF patients was still in development during the initial period of establishment of the MDT-HF clinic.11 Of note, aspirin and statin use was also high in our MDT-HF patients, again due to higher rates of ischaemic cardiomyopathy. It was reassuring to observe how a large proportion of patients attending the MDT-HF clinic were on either three or four GDMT (87.1% combined; Table 3).

Counselling Provided, and Drugrelated Problems Identified During Multidisciplinary Team Clinic Visits

Article image

The counselling provided during our MDT-HF clinic aims at providing holistic care to HF patients.7,8,20 Alongside education on self-care and medication management, there is an emphasis on providing structured physical and psychological support following hospitalisation, given that this may be traumatic for many. In fact, rates of mood disorders are among the highest with regards to the associated comorbidities in HF, with 20% of HF patients experiencing depression, half of whom have severe depression.11 Frailty, sarcopenia and cachexia also provide unique challenges in HF patients, underlining the need for a multidisciplinary approach incorporating physiotherapy, nutrition and rehabilitation services.11 Lifestyle counselling and consultation enable gaps in care to be identified, which then lead to referrals to a physiotherapist, occupational therapist or counsellors when indicated. The establishment of a structured service, such as an MDT-HF clinic, enables these adjunct services to be more accessible to patients. Unfortunately, the Kansas City Cardiomyopathy Questionnaire score was not incorporated into the design of the initial MDT-HF clinic, which would have assisted in highlighting gaps in the care of HF patients, specifically pertaining to psychosocial domains.21,22 As of June 2022, efforts are being made to improve on the design of the clinic, and incorporation of the score is being carefully considered.

Clinical Outcomes Following Index Multidisciplinary Team Heart Failure Clinic Visits

Article image

There is still much debate with regard to streamlining the terms of the models of care and services provided, focusing largely on whether it is best delivered in a community versus a hospital setting; and whether remote monitoring and management can be incorporated into such comprehensive care, especially given the recent COVID-19 pandemic and its impact on healthcare systems worldwide.7–9,23–26 Nevertheless, adoption of an MDT approach has been shown to be cost-effective; it has improved adherence to medical treatment, reduced the length of inpatient stay, and can lead to lower hospital readmissions and mortality.


This analysis is limited by a small sample population with no validation analysis performed to compare experiences with other MDT efforts worldwide. However, to our knowledge, our MDT-HF clinic experience was unique in its set-up and there have not been any other reports published locally or regionally. Therefore, the analysis provided remains valuable for future research and development. Furthermore, unfortunately, data on HF patients seen in the ambulatory setting in our centre prior to the establishment of the MDT-HF clinic are not readily accessible for comparison. We thus decided to keep the manuscript descriptive, at best, to share our local experience in piloting an MDT-HF clinic. It would be beneficial, however, to compare the data presented in our paper with those of other clinical settings (i.e. primary care management, general cardiology clinics or other dedicated HF clinic initiatives) to understand the true extent of benefit from running an MDT-HF clinic before expansion of such services regionally, especially in key endpoints, such as mortality and readmissions.


Although definitions may differ between healthcare systems, MDT-based services undeniably offer evidence-based, holistic care to patients, regardless of the disease or condition being managed. This is especially important in complex, chronic conditions such as HF. Hopefully, our description of the establishment of the first MDT-HF clinic targeted at transitional care will encourage the development of similar services across the region, and subsequently improve outcomes in HF patients, which remain poor in our region.

Clinical Perspective

  • Optimisation of guideline-directed medical therapy (GDMT) during the ‘vulnerable phase’ of heart failure is key.
  • Multidisciplinary team heart failure clinics have been shown to be beneficial in increasing key GDMT prescriptions.
  • Furthermore, adopting a multidisciplinary team approach has been shown to be cost-effective, has improved adherence to medical treatment, reduced length of inpatient stay, and can lead to lower hospital readmissions and mortality.


  1. Greene SJ, Triana TS, Ionescu-Ittu R, et al. Patients hospitalized for de novo versus worsening chronic heart failure in the United States. J Am Coll Cardiol 2021;77:1023–5.
    Crossref | PubMed
  2. Raja Shariff RE, Kasim S, Borhan MK, Yusoff MR. Acute heart failure – the ‘real’ Malaysian experience: an observational study from a single non-cardiac centre. Proc Singapore Healthc 2021;30:218–24.
  3. Ling HS, Chung BK, Chua PF, et al. Acute decompensated heart failure in a non-cardiology tertiary referral centre. BMC Cardiovasc Disord 2020;20:511.
    Crossref | PubMed
  4. Greene SJ, Fonarow GC, Vaduganathan M, et al. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 2015;12:220–9.
    Crossref | PubMed
  5. Greene SJ, Butler J, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. Eur J Heart Fail 2022;24:227–9.
    Crossref | PubMed
  6. Mohd Ghazi A, Teoh CK, Abdul Rahim AA. Patient profiles on outcomes in patients hospitalized for heart failure: a 10-year history of the Malaysian population. ESC Heart Fail 2022;9:2664–75.
    Crossref | PubMed
  7. Essa H, Walker L, Mohee K, et al. Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance. Open Heart 2022;9:e001979.
    Crossref | PubMed
  8. Morton G, Masters J, Cowburn PJ. Multidisciplinary team approach to heart failure management. Heart 2018;104:1376–82.
    Crossref | PubMed
  9. Van Spall HGC, Fonarow GC, Mamas MA. Underutilization of guideline-directed medical therapy in heart failure: can digital health technologies PROMPT change? J Am Coll Cardiol 2022;79:2214–8.
    Crossref | PubMed
  10. Shen L, Jhund PS, Docherty KF, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J 2022;43:2573–87.
    Crossref | PubMed
  11. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726.
    Crossref | PubMed
  12. Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J 2021;42:681–3.
    Crossref | PubMed
  13. Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med 2018;15:e1002541.
    Crossref | PubMed
  14. Rajadurai J, Tse HF, Wang CH, et al. Understanding the epidemiology of heart failure to improve management practices: an Asia-Pacific perspective. J Card Fail 2017;23:327–39.
    Crossref | PubMed
  15. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2019;139:e840–78.
    Crossref | PubMed
  16. Clark AL, Kalra PR, Petrie MC, et al. Change in renal function associated with drug treatment in heart failure: national guidance. Heart 2019;105:904–10.
    Crossref | PubMed
  17. Mullens W, Damman K, Testani JM, et al. Evaluation of kidney function throughout the heart failure trajectory: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;22:
    Crossref | PubMed
  18. Ahmad T, Jackson K, Rao VS, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation 2018;137:2016–28.
    Crossref | PubMed
  19. Januzzi JL Jr, Maisel AS, Silver M, et al. Natriuretic peptide testing for predicting adverse events following heart failure hospitalization. Congest Heart Fail 2012;18:S9–13.
    Crossref | PubMed
  20. McDonagh TA. Lessons from the management of chronic heart failure. Heart 2005;91(Suppl 2):ii24–7.
    Crossref | PubMed
  21. Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 2020;76:2379–90.
    Crossref | PubMed
  22. Masterson Creber R, Polomano R, Farrar J, Riegel B. Psychometric properties of the Kansas City Cardiomyopathy Questionnaire (KCCQ). Eur J Cardiovasc Nurs 2012;11:197–206.
    Crossref | PubMed
  23. Frankenstein L, Fröhlich H, Cleland JG. Multidisciplinary approach for patients hospitalized with heart failure. Rev Esp Cardiol (Engl Ed) 2015;68:885–91.
    Crossref | PubMed
  24. Silva-Cardoso J, Juanatey JRG, Comin-Colet J, et al. The future of telemedicine in the management of heart failure patients. Card Fail Rev 2021;7:e11.
    Crossref | PubMed
  25. Gensini GF, Alderighi C, Rasoini R, et al. Value of telemonitoring and telemedicine in heart failure management. Card Fail Rev 2017;3:116–21.
    Crossref | PubMed
  26. Gorodeski EZ, Goyal P, Cox ZL, et al. Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America. J Card Fail 2020;26:448–56.
    Crossref | PubMed